Статины во время пандемии COVID-19: новое прочтение легендарной саги

V. E. Oleinikov; I. V. Avdeeva; N. V. Burko; L. I. Salyamova; K. N.  Makarova

doi:10.34687/2219-8202.JAD.2021.03.0001

Authors

V. E. Oleinikov FSBEI HPE "Penza State Medical University"
I. V. Avdeeva "Penza State University", Department "Therapy", Penza, Russia
N. V. Burko ФГБОУ ВО «Пензенский государственный университет», кафедра «Терапия», г. Пенза
L. I. Salyamova ФГБОУ ВО «Пензенский государственный университет», кафедра «Терапия», г. Пенза
K. N. Makarova ФГБОУ ВО «Пензенский государственный университет», кафедра «Терапия», г. Пенза

DOI:

https://doi.org/10.34687/2219-8202.JAD.2021.03.0001

Keywords:

COVID-19, statins, pleyotropy, inflammation, endothelial dysfunction.

Abstract

In the context of the novel coronavirus infection COronaVIrus Disease-2019 (COVID-19) pandemic which has had an unprecedented impact on both health systems around the world and the health and lives of millions of people, interest in statins is justified, given their pleiotropy, in particular, anti-inflammatory effect, and widespread use in the population. The biochemical mechanisms of the statins effect on inflammation are described in detail, the results of international clinical trials (MIRACLE, PROVE IT-TIMI, REVERSAL, PRINCE, JUPITER) are presented. The data on the use of statins as concomitant therapy for sepsis and pneumonia were analyzed. The positive effects of these drugs in COVID-19 are indicated (influence on inflammation, in particular, "cytokine storm", endothelial dysfunction, atherosclerotic plaque instability, myocardial hypoxia / ischemia, oxidative stress, thrombus formation).